USANA Health Sciences (NYSE:USNA) Trading Down 2.1% Following Insider Selling

USANA Health Sciences, Inc. (NYSE:USNA) shares were down 2.1% on Friday after an insider sold shares in the company. The stock traded as low as $29.79 and last traded at $29.73. Approximately 10,077 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 100,948 shares. The stock had previously closed at $30.37.

Specifically, insider Joshua Foukas sold 5,732 shares of the company’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Mulham Mulham sold 3,234 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the transaction, the insider now owns 12,775 shares in the company, valued at approximately $421,319.50. This represents a 20.20 % decrease in their position. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on USNA shares. Sidoti cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. DA Davidson cut their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. Finally, StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th.

USANA Health Sciences Stock Down 2.2 %

The firm has a market capitalization of $566.27 million, a PE ratio of 10.50, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98. The company’s 50-day simple moving average is $32.67 and its 200 day simple moving average is $36.01.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. The company had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. On average, sell-side analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd acquired a new position in shares of USANA Health Sciences during the fourth quarter valued at about $28,000. Safe Harbor Fiduciary LLC purchased a new stake in USANA Health Sciences during the 3rd quarter worth approximately $30,000. KBC Group NV increased its stake in USANA Health Sciences by 96.6% during the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after purchasing an additional 519 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of USANA Health Sciences in the fourth quarter worth $83,000. Finally, Quantbot Technologies LP acquired a new stake in shares of USANA Health Sciences during the fourth quarter worth $132,000. 54.25% of the stock is owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.